Drug Device Interactions

The first implantable cardioverter-defibrillator (ICD) was placed in 1982. Since that time, their use has expanded exponentially. Several large clinical trials have demonstrated the superiority of ICDs compared with pharmacological therapy for the secondary prevention of arrhythmic death and possibly as primary therapy for patients at risk for ventricular arrhythmias.

Combination therapy employing both antiarrhyth-mic drugs and ICDs is becoming more common. While the antiarrhythmic drugs have multiple positive effects on the overall therapy, they may alter the frequency of ICD discharge and the ability of the device to detect ventricular tachycardia. A serious concern is the potential for a given drug to increase the defibrillation threshold, thereby rendering the device ineffective.

In general, drugs that block the sodium channel and shorten the action potential tend to increase the defib-rillation threshold. Drugs that prolong repolarization also tend to decrease this threshold. These changes have obvious important ramifications for patients with ICDs.

Effects of antiarrhythmic drugs on defibrillation thresholds:

Peripheral Neuropathy Natural Treatment Options

Peripheral Neuropathy Natural Treatment Options

This guide will help millions of people understand this condition so that they can take control of their lives and make informed decisions. The ebook covers information on a vast number of different types of neuropathy. In addition, it will be a useful resource for their families, caregivers, and health care providers.

Get My Free Ebook

Post a comment